Net sales were $1.283 billion for the fourth quarter, compared to $1.794 billion in the prior year's fourth quarter. Selling, general and administrative (“SG&A”) expenses were $282.5 million for the ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Fulgent Genetics has a low Price/Book ratio and promising drug candidates. Key trial results are expected in May 2025. Read ...

Herc will finance the offer through a combination of available cash on hand, proceeds from the sale of marketable securities ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Cash, Cash Equivalents and Marketable Securities As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $316.9 million, as compared to $388.3 million as of September 30 ...

Trust and security play an important role in every financial transaction, so there is no space for fraud or tampering. Because there are more and more digital payments and online banking, maintaining ...

Increased financial flexibility and runway to advance an expanded late-stage pipeline and build commercial capabilities. Alumis and ACELYRIN had cash, cash equivalents and marketable securities of ...

Fourth Quarter and Full Year 2024 Financial Highlights Cash, cash equivalents, and marketable ... forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 ...

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024 Cash, cash equivalents, and marketable debt securities totaled $706.7 million as of December 31, 2024 compared to $ ...

Financial institutions worldwide are under mounting pressure to strengthen cybersecurity measures as new regulations aim to curb rising threats. In the United States, the Securities and Exchange ...